Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists
Higher doses would accelerate fat loss but potentially amplify the side effects that could compromise training quality
Diabetes Care (2013) 36:294551
In addition to providing coverage of these drugs for obesity, which would be a new indication in Medicare and in most states under Medicaid, these efforts will also allow beneficiaries in participating states and Part D plans to access GLP-1s for obesity at a lower out-of-pocket cost than if they were to purchase them with cash at the direct-to-consumer prices offered by the manufacturers
At-home Biomarkers test kit 17 advanced lab markers that track your metabolic, cardiovascular, and hormonal health in addition to measuring inflammation and key nutrients over time
For organizations navigating the GLP-1 landscape specifically, Cypris enables continuous monitoring of poly-agonist patent filings, delivery technology innovations, and combination therapy claims across global jurisdictions